Skip to Main Content

Filter:

Residents' Clinics

2 Results

Letter to the Editor
Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study
Mayo Clinic Proceedings
Vol. 93Issue 12p1874–1876Published in issue: December, 2018
- Shih-Wei Lai
- Cheng-Li Lin
- Kuan-Fu Liao
Cited in Scopus: 1
Dipeptidyl peptidase-4 inhibitor is an incretin-based agent used to treat type 2 diabetes mellitus, which has been available in the Taiwan market since 2009.¹ Pancreatic cancer was the eighth leading cause of cancer death in Taiwan in 2017.² At present, no definite evidence is available on the association between pancreatic cancer and dipeptidyl peptidase-4 inhibitors in Taiwan. To evaluate this issue, a population-based case-control study was conducted using the database of the Taiwan National Health Insurance Program with 23 million citizens living in the independent country of Taiwan.
Residents' Clinic
22-Year-Old Woman With Severe Microcytic Anemia
Mayo Clinic Proceedings
Vol. 75Issue 8p861–864Published in issue: August, 2000
- Angela R. Shouo
- Ronald S. Go
- Ayalew Tefferi
Cited in Scopus: 5
A 22–year-old woman who had no notable previous medical history reported increasing fatigue during the past few months. Her mother noticed that she looked pale and suggested she visit her family physician. Her family and personal histories were noncontributory. Findings on physical examination were remarkable only for pallor. In particular, she had no hepatosplenomegaly or lymphadenopathy.